Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders

Huseyin Firat; Sabrina Danilin; Yvan Devaux; Lu Zhang; Przemyslaw Leszek; Eric Schordan; Samir Ounzain; Thierry Pedrazzini

Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders

Huseyin Firat (Inventor), Sabrina Danilin (Inventor), Yvan Devaux (Inventor), Lu Zhang (Inventor), Przemyslaw Leszek (Inventor), Eric Schordan (Inventor), Samir Ounzain (Inventor), Thierry Pedrazzini (Inventor)

Cardiovascular Research Unit

Research output: Patent

Abstract

The present invention provides methods for diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessement/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the asessement of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different pathophysiological events cardiac function and represent a potential target for therapeutical approaches.

Original language	English
IPC	WO 2018/229046
Publication status	Published - 20 Dec 2018

Cite this

@misc{9c80444a2ee14cc1983f3b28f75666fe,

title = "Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders",

abstract = "The present invention provides methods for diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessement/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the asessement of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different pathophysiological events cardiac function and represent a potential target for therapeutical approaches.",

author = "Huseyin Firat and Sabrina Danilin and Yvan Devaux and Lu Zhang and Przemyslaw Leszek and Eric Schordan and Samir Ounzain and Thierry Pedrazzini",

year = "2018",

month = dec,

day = "20",

language = "English",

type = "Patent",

note = "WO 2018/229046",

}

TY - PAT

T1 - Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders

AU - Firat, Huseyin

AU - Danilin, Sabrina

AU - Devaux, Yvan

AU - Zhang, Lu

AU - Leszek, Przemyslaw

AU - Schordan, Eric

AU - Ounzain, Samir

AU - Pedrazzini, Thierry

PY - 2018/12/20

Y1 - 2018/12/20

N2 - The present invention provides methods for diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessement/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the asessement of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different pathophysiological events cardiac function and represent a potential target for therapeutical approaches.

AB - The present invention provides methods for diagnosing, monitoring and prognostication of primary and secondary cardiac disorders in a subject based on lncRNA expression. The invention also provides methods for predicting heart failure after myocardial infarction, and differenciation of Ischemic versus non-ischemic Heart Failure. The assessement/quantification of these lncRNAs may also be used as a marker for monitoring drug-induced cardiac toxicities and for the asessement of cardiac involvement during systemic diseases and others disorders/toxicities impacting cardiac function. These lncRNAs are cardiac tissue enriched and may be involved in different pathophysiological events cardiac function and represent a potential target for therapeutical approaches.

M3 - Patent

ER -

Diagnostic, prognostic and therapeutic uses of long noncoding RNAs for pathologies and toxicities inducing heart disorders

Abstract

Fingerprint

Cite this